Gadoteridol

钆特醇

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NameGadoteridol
Drug Alias Namegadoteridolum加多利道卡道特依道ProHance普海司 +[7] 
ClassificationSmall moleculesDiagnostic agent (In vivo) > Contrast agent
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsContrast agentsCentral Nervous System DiseasesMultiple Sclerosis, Chronic Progressive +[4] 
Global Approved IndicationsContrast agentsCentral Nervous System Diseases
Approved Indications in ChinaContrast agents
Original Approved Country/TerritoryUnited States
Original Approved Date1992/11/16
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBracco International Bv
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityBracco SpaBracco Imaging Italia Srl
Inactive CompaniesN/A
Active IndicationsContrast agentsCentral Nervous System DiseasesMultiple Sclerosis, Chronic Progressive +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeV08CA04
Related LinksWikipediaDrugBankKEGG